Trials / Completed
CompletedNCT02734160
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as galunisertib administered in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody durvalumab in participants with refractory metastatic pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galunisertib | Administered orally |
| DRUG | Durvalumab | Administered IV |
Timeline
- Start date
- 2016-06-15
- Primary completion
- 2018-08-02
- Completion
- 2019-04-17
- First posted
- 2016-04-12
- Last updated
- 2019-08-05
Locations
11 sites across 5 countries: United States, France, Italy, South Korea, Spain
Source: ClinicalTrials.gov record NCT02734160. Inclusion in this directory is not an endorsement.